objectives to summarize and compare evidence on harms in sildenafil and placebotreated men with erectile dysfunction ed in a systematic review and metaanalysismethods randomized placebocontrolled trials rcts were identified using an electronic search in medline embase psycinfo scopus and cochrane centralthe rates of any adverse events aes most commonly reported aes withdrawals because of adverse events and serious adverse events were ascertained and compared between sildenafil and placebo groupsthe results of men with ed were stratified by clinical conditionsstatistical heterogeneity was exploredmetaanalyses based on randomeffects model were also performedresults a total of 49 rcts were includedsildenafiltreated men had a higher risk for allcause aes rr  156 95 ci 138 176 headache flushing dyspepsia and visual disturbances compared with placebotreated menthe magnitude of excess risk was greater in fixed than in flexibledose trialsthe rates of serious adverse events and withdrawals because of adverse events did not differ in sildenafil vs placebo groupsa higher dose of sildenafil corresponded to a greater risk of aesthe increased risk of harms was observed within and across clinically defined specific groups of patientsconclusions there was a lack of rcts reporting longterm 6 months harms datain shortterm trials men with ed randomized to sildenafil had an increased risk of allcause any aes headache flushing dyspepsia and visual disturbancesthe exploration of different modes of dose optimization of sildenafil may be warranted